

Tuberculosis profile: Russian Federation

Population 2019: 146 million

Estimates of TB burden*, 2019

	Number	(Rate per 100 000 population)
Total TB incidence	73 000 (47 000-104 000)	50 (32-71)
HIV-positive TB incidence	17 000 (11 000-24 000)	12 (7.5-17)
MDR/RR-TB incidence**	39 000 (25 000-56 000)	27 (17-38)
HIV-negative TB mortality	8 400 (7 900-8 900)	5.8 (5.4-6.1)
HIV-positive TB mortality	1 300 (560-2 300)	0.88 (0.38-1.6)

Estimated proportion of TB cases with MDR/RR-TB*, 2019

New cases	35% (35-36)
Previously treated cases	71% (70-71)

Universal health coverage and social protection*


TB treatment coverage (notified/estimated incidence), 2019	100% (71-160)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2019	14% (9-20)

TB case notifications, 2019

Total new and relapse	73 328
- % tested with rapid diagnostics at time of diagnosis	80%
- % with known HIV status	96%
- % pulmonary	92%
- % bacteriologically confirmed ^	54%
- % children aged 0-14 years	3%


Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)



HIV-negative TB mortality

(Rate per 100 000 population per year)



Incidence, Notified cases by age group and sex, 2019

(Number)

- % women	29%
- % men	68%
Total cases notified	103 979

TB/HIV care in new and relapse TB patients, 2019

	Number	(%)
Patients with known HIV status who are HIV-positive	16 453	23%
- on antiretroviral therapy	11 761	71%

Drug-resistant TB care, 2019


% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	89%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	96%
Laboratory-confirmed cases - MDR/RR-TB ^^	27 207
Patients started on treatment - MDR/RR-TB ^^	29 547
Laboratory-confirmed cases - XDR-TB ^^	5 699
Patients started on treatment - XDR-TB ^^	6 010
MDR/RR-TB cases tested for resistance to any fluoroquinolone	25 331

Treatment success rate and cohort size


	Success	Cohort
New and relapse cases registered in 2018	69%	59 850
Previously treated cases, excluding relapse, registered in 2018	48%	8 876
HIV-positive TB cases registered in 2018	44%	12 013
MDR/RR-TB cases started on second-line treatment in 2017	55%	22 901
XDR-TB cases started on second-line treatment in 2017	41%	4 140

TB preventive treatment, 2019


% of HIV-positive people (newly enrolled in care) on preventive treatment	
---	--



Treatment success rate



Total budget



% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment 100% (100-100)

TB financing

National TB budget, 2020 (US\$ millions)	1 571
- Funding source, domestic	100%
- Funding source, international	0%
- unfunded	0%

* Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

^ Calculated for pulmonary cases only

^^ Includes cases with unknown previous TB treatment history

^^^ Includes patients diagnosed before 2019 and patients who were not laboratory-confirmed

Generated 2020-10-21 by the World Health Organization (<https://www.who.int/tb/data/>)